Stem Cell Legislation & Policy

Key laws and policies that shaped funding, ethics, and research practice.

July 20, 2026

Stem Cell Therapeutic and Research Reauthorization Act of 2025 (H.R. 5160)

Reauthorizes and updates the Stem Cell Therapeutic and Research Act of 2005. The bill passed the House by voice vote on July 20, 2026, and was sent to the Senate.

Impact: If enacted, it would reauthorize funding for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory, with several updates to the Cord Blood Inventory program.
January 22, 2026

NIH Ends Funding for Research Using Human Fetal Tissue

The National Institutes of Health announced that, effective immediately, NIH funds would no longer support research involving human fetal tissue from elective abortions.

Impact: The policy applies to NIH intramural research and all NIH-supported extramural research. NIH also said it would seek public comment on technologies that could reduce reliance on human embryonic stem cells.
November 3, 2020

California Proposition 14: Stem Cell Research Institute Bond Initiative

California voters approved Proposition 14 with 51.1% of the vote, authorizing $5.5 billion in general obligation bonds for the California Institute for Regenerative Medicine (CIRM).

Impact: Refunded CIRM after its Proposition 71 funds ran low, set aside $1.5 billion for brain and nervous system diseases, and expanded CIRM’s governing board from 29 to 35 members.
June 3, 2019

United States v. US Stem Cell Clinic

A federal court in Florida ruled that the stromal vascular fraction cell product made by US Stem Cell Clinic from patients’ fat was a drug subject to FDA regulation, and granted the FDA a permanent injunction.

Impact: The Eleventh Circuit Court of Appeals affirmed the ruling on June 2, 2021. The case confirmed the FDA’s authority over clinics selling unapproved stem cell treatments.
May 30, 2018

Right to Try Act (S. 204)

President Donald Trump signed the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, Public Law 115-176.

Impact: Allows eligible patients with life-threatening conditions who have exhausted approved treatments and cannot join a clinical trial to seek certain investigational drugs that have completed a phase 1 trial.
November 16, 2017

FDA Regenerative Medicine Policy Framework

The FDA announced a policy framework for regenerative medicine products, including final guidance on when human cells and tissues are minimally manipulated and intended for homologous use.

Impact: Gave manufacturers a period of enforcement discretion to determine whether they needed FDA approval, while the agency focused enforcement on higher-risk products.
December 13, 2016

21st Century Cures Act (Public Law 114-255)

President Barack Obama signed the 21st Century Cures Act. Section 3033 created the Regenerative Medicine Advanced Therapy (RMAT) designation.

Impact: RMAT designation lets the FDA expedite development and review of cell therapies and other regenerative medicine products for serious or life-threatening conditions.
December 18, 2015

Stem Cell Therapeutic and Research Reauthorization Act of 2015 (H.R. 2820)

Became Public Law 114-104, reauthorizing the Stem Cell Therapeutic and Research Act of 2005.

Impact: Continued funding for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2020.
November 25, 2014

Japan’s Act on the Safety of Regenerative Medicine and PMD Act Take Effect

Japan’s Act on the Safety of Regenerative Medicine and the revised Pharmaceuticals and Medical Devices (PMD) Act took effect.

Impact: The Safety Act covers clinical research and medical use of processed cells. The PMD Act created a conditional, time-limited approval pathway for regenerative medical products.
October 18, 2011

Brüstle v Greenpeace (Case C-34/10)

The Court of Justice of the European Union ruled that an invention cannot be patented in the EU if it requires the prior destruction of human embryos or their use as base material.

Impact: Limited patents on human embryonic stem cell techniques across the European Union.
August 23, 2010

Sherley v. Sebelius

A federal district judge issued a preliminary injunction blocking NIH funding of human embryonic stem cell research under its 2009 guidelines, finding it likely violated the Dickey-Wicker Amendment.

Impact: The D.C. Circuit Court of Appeals vacated the injunction on April 29, 2011, and the Supreme Court declined to hear the case on January 7, 2013, leaving NIH funding in place.
July 7, 2009

NIH Guidelines for Human Stem Cell Research

The National Institutes of Health published final guidelines, effective the same day, implementing Executive Order 13505.

Impact: Allowed NIH funding for research using human embryonic stem cell lines derived from embryos donated by IVF patients with informed consent, and created the NIH Human Embryonic Stem Cell Registry.
March 9, 2009

Executive Order 13505: Removing Barriers to Responsible Scientific Research Involving Human Stem Cells

The purpose of this order by President Barack Obama was to remove "limitations on scientific inquiry, to expand NIH support for the exploration of human stem cell research, and in so doing to enhance the contribution of America's scientists to important new discoveries and new therapies for the benefit of humankind."

Impact: Allowed NIH to support and conduct human embryonic stem cell research that had been limited by previous Presidential actions.
November 13, 2008

UK Human Fertilisation and Embryology Act 2008

The UK Human Fertilisation and Embryology Act 2008 received Royal Assent, updating the 1990 Act.

Impact: Brought human admixed embryos, which contain both human and animal material, under licensing by the Human Fertilisation and Embryology Authority, with a 14-day limit.
November 4, 2008

Michigan Proposal 2

Michigan voters approved Proposal 2 by 52.6% to 47.4%, amending the state constitution to allow embryonic stem cell research permitted under federal law.

Impact: Allowed research on embryos left over from fertility treatment that would otherwise be discarded, with donor consent, and banned buying or selling embryos.
November 13, 2007

EU Regulation on Advanced Therapy Medicinal Products (No 1394/2007)

The European Parliament and Council adopted Regulation (EC) No 1394/2007 on advanced therapy medicinal products, which applied from December 30, 2008.

Impact: Set EU-wide rules for authorizing gene therapies, somatic cell therapies and tissue-engineered products through the European Medicines Agency.
June 20, 2007

Executive Order 13435: Expanding Approved Stem Cell Lines in Ethically Responsible Ways

On June 20, 2007, President George W. Bush vetoed the Stem Cell Research Enhancement Act of 2007 (S. 5). Alongside his veto, he issued an Executive Order promoting alternative, ethically responsible scientific methods—such as reprogramming adult skin cells—to create pluripotent stem cells without the destruction of human embryos.

Impact: Directed HHS to rename the Human Embryonic Stem Cell Registry the Human Pluripotent Stem Cell Registry and to add pluripotent stem cell lines derived without creating or destroying human embryos.
November 7, 2006

Missouri Amendment 2: Stem Cell Research and Cures Initiative

Missouri voters approved Amendment 2 with 51.2% of the vote, amending the state constitution.

Impact: Allowed any stem cell research permitted under federal law to be conducted in Missouri, and banned human cloning.
July 18-19, 2006

Stem Cell Research Enhancement Act (H.R. 810)

The Stem Cell Research Enhancement Act (H.R. 810) aimed to expand federal funding for human embryonic stem cell research by allowing the use of stem cells derived from embryos donated from in vitro fertilization clinics. It was vetoed by President George W. Bush on July 19, 2006, who argued it crossed a moral boundary by supporting the destruction of human embryos. The same day, the House failed, 235-193, to override President Bush’s veto, falling short of the two-thirds majority needed to override a presidential veto.

Impact: Had the bill become law, it would have allowed federal funding for research using human embryonic stem cell lines derived from embryos donated by fertility clinics, regardless of the date the lines were created.
December 20, 2005

Stem Cell Therapeutic and Research Act of 2005 (Public Law 109-129)

President George W. Bush signed the Stem Cell Therapeutic and Research Act of 2005.

Impact: Created the National Cord Blood Inventory and the C.W. Bill Young Cell Transplantation Program to support bone marrow and cord blood transplants.
November 2, 2004

The California Stem Cell Research and Cures Act (Proposition 71)

The Act makes conducting stem cell research a state constitutional right. It authorizes the sale of general obligation bonds to allocate three billion dollars over a period of ten years to stem cell research and research facilities. Although the funds could be used to finance all kinds of stem cell research, it gives priority to human embryonic stem cell research.

Impact: Created the California Institute for Regenerative Medicine (CIRM), which is in charge of making "grants and loans for stem cell research, for research facilities, and for other vital research opportunities to realize therapies."
January 4, 2004

New Jersey Stem Cell Research Law

New Jersey Governor James McGreevey signed a law (P.L. 2003, c. 203) permitting research on human embryonic, germ and adult stem cells.

Impact: New Jersey became the second state, after California, to expressly permit embryonic stem cell research. The law banned human reproductive cloning.
August 9, 2001

President Bush Limits Federal Funding of Embryonic Stem Cell Research

President George W. Bush announced that federal funds could be used only for research on human embryonic stem cell lines that already existed as of August 9, 2001.

Impact: Federal funding was not available for research on lines derived after that date. Research with private or state funds was not affected.
January 31, 2001

UK Human Fertilisation and Embryology (Research Purposes) Regulations 2001

New UK regulations came into force allowing licensed embryo research for additional purposes.

Impact: Permitted embryo research to increase knowledge about embryo development and serious disease and to develop treatments, opening the way for licensed human embryonic stem cell research in the UK.
January 26, 1996

The Dickey-Wicker Amendment

Congress bans the federal funding for research on embryos through the Dickey-Wicker Amendment, named after its sponsors Jay Dickey (R-AR) and Roger Wicker (R-MS). It was first enacted in the Balanced Budget Downpayment Act, I (Public Law 104-99), signed on January 26, 1996.

Impact: The amendment prohibits the use of federal funds for "the creation of human embryo or embryos for research purposes; or research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero."
November 1, 1990

UK Human Fertilisation and Embryology Act 1990

The UK Human Fertilisation and Embryology Act 1990 received Royal Assent.

Impact: Created the Human Fertilisation and Embryology Authority to license IVF and human embryo research, and set a 14-day limit on keeping embryos for research.